• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Child Neurol Open . A Favorable Treatment Outcome in RANBP2 and Influenza Associated Acute Necrotizing Encephalitis

tetano

Editor, Senior Moderator
Child Neurol Open


. 2022 Dec 13;9:2329048X221143689.
doi: 10.1177/2329048X221143689. eCollection 2022 Jan-Dec.
A Favorable Treatment Outcome in RANBP2 and Influenza Associated Acute Necrotizing Encephalitis


Fernando Galan[SUP] 1 2 [/SUP], Douglas R Nordli[SUP] 2 [/SUP], Milad Yazdani[SUP] 1 [/SUP], Jessica Klein[SUP] 3 [/SUP]



Affiliations
Free PMC article

Abstract

In current literature, there is uncertainty in the pathophysiology and management of influenza-associated Acute Necrotizing Encephalitis. Because of this and the rarity of the disease, no clear treatment guidelines exist. It is thought that treatment after 24 h of symptom onset or known brainstem involvement are poor predictors of outcome. Here, we present a case that provides support for aggressive management of the inflammatory cascade with combination high-dose steroid, immunoglobulin, and anti-viral therapy with oseltamivir despite initiation after 24 h from symptom onset, brainstem involvement, and a pathogenic RANBP2 gene mutation which mechanistically increases oxidative stress, cytokine effects, and possibly viral invasion into brain tissue and vasculature.

Keywords: autoimmune; children; cognition; encephalitis.
 
Back
Top